Cancer vaccines and tumor immunity

Cancer vaccine development has changed from a small-scale academic enterprisein to an applied science requiring a large, clinical-research infrastructure.Cancer Vaccines and Tumor Immunity will serve a unique role in that it will present as a continuum the basic science discoveries that have moved forward into clinical trials. It will serve as a one-stop, concise reference for all those interested in cancer vaccines, summarizing where we have come from, demonstrating what we are currently doing, and identifying the next major advances. INDICE: FORWARD. Cancer Vaccines and Cancer Immunotherapy. A New Paradigm.Jeffrey Schlom. OVERVIEW. Chapter 1. Cancer Vaccines. Progress and Promise. Rimas J. Orentas, Bryon Johnson, and James Hodge. PART I. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE. Chapter 2. Fully Synthetic Carbohydrate-Based Anti-Tumor Vaccines. Rebecca M. Wilson and Samuel J. Danishefsky. Chapter 3. Bacillus Calmette-Guerin Immunotherapy of Genitourinary Cancer. Donald L. Lamm. Chapter 4. Stimulation of Toll-like Receptor 9 for Enhancing Vaccination. Daniel E. Speiser and Arthur M. Krieg. PART II. ANTIGEN-SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS. Chapter 5. Polyepitope Vaccines. Corey Smith and Rajiv Khanna. Chapter 6. Antigen-Specific Cancer Immunotherapy: HPV-Associated Cervical Cancer as a Model System. Shaw-Wei D. Tsen, Chien-Fu Hung, and T.-C. Wu. Chapter 7. Poxviral vectors for cancer vaccines: state of the art. Elizabeth K. Wansley. Chapter 8. Immunotherapeutic strategiesagainst cancer using Listeria monocytogenes as a vector for tumor antigens. Nicholas C. Souders, Thorsten Verch and Yvonne Paterson. Chapter 9. Coupling Innate and Adaptive Immunity with Yeast-based Cancer Immunotherapy. Sibyl Munson, Joanne Parker, Tom King, Yingnian Lu, Victoria Kelley, Zhimin Guo, Virginia Borges, and Alex Franzusoff. PART III. CELL-BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY. Chapter 10. Allogeneic Whole Cell Vaccines. John Copier and Angus Dalgleish. Chapter 11. Jump-Starting Tumor Immunity with Breast Cancer Therapeutics. Leisha A. Emens. Chapter 12. T Regulatory Cell Manipulation in Tumor Immunotherapy. Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J. Curiel. Chapter 13. Tumor Vaccination after Autologous HSCT: Whathas been Learned from Experimental Models? Weiqing Jing and Bryon D. Johnson.Chapter 14. Vaccines in the Setting of Hematopoietic Stem Cell Transplantation. Ronald Gress and Claude Sportes. Chapter 15. Intra-tumor generation of vigorous anti-tumor immune responses. Ping Yu and Yang-Xin Fu. Chapter 16. Cancer Immunotherapy: Untapping the Potential of Co-Stimulatory Molecules Beyond CTLA-4. Mathew Augustine, and Lieping Chen. PART IV. DEFINING EFFECTIVE CLINICAL RESPONSES. Chapter 17. Immune Evaluation of Cancer Vaccines. Theresa L. Whiteside. Chapter 18. Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy. Seunghee Kim-Schulze, Moshe Ornstein and Howard L. Kaufman.

• ISBN: 978-0-470-07474-9
• Editorial: John Wiley & Sons
• Encuadernacion: Cartoné
• Páginas: 352
• Fecha Publicación: 22/02/2008
• Nº Volúmenes: 1
• Idioma: Inglés